SPMS health costs are high, and higher still for younger patients and those with severe disability, a real-world study in ...

In the Phase III SELECT-GCA trial, Rinvoq (upadacitinib) 15 mg with a 26-week glucocorticoid taper significantly improved ...

Discover why BTK inhibitors have attracted interest for treating multiple sclerosis, as a few late-stage candidates close in ...

Tolebrutinib did not show superiority over Aubagio (teriflunomide) in reducing relapse rates or MRI-detected inflammatory ...

--U.S. FDA Delays: Sanofi is potentially exposed to any delays in reviews due to recently announced staff firings at the U.S. Food and Drug Administration. Its anti-inflammatory drug Dupixent was ...

The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has approved ...